Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

Atheir Abbas, Bryan L. Roth

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Background: Pimavanserin tartrate is the first 5-HT2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. Objective: To discuss the potential of pimavanserin to fill multiple therapeutic needs. Methods: The problems with currently approved antipsychotics and sleep agents are explored to highlight how pimavanserin might address some longstanding issues in the treatment of psychosis and insomnia. Results/conclusions: In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L-dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals.

Original languageEnglish (US)
Pages (from-to)3251-3259
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number18
DOIs
StatePublished - Dec 2008
Externally publishedYes

Keywords

  • 5-HT
  • Parkinson's Disease
  • antipsychotic
  • inverse agonist
  • pimavanserin
  • psychosis
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders'. Together they form a unique fingerprint.

Cite this